Research & Literature

Role of Rhizomys pruinosus as a natural animal host of Penicillium marneffei in Guangdong, China.

Huang X, He G, Lu S, et al.

Microbial biotechnology 2015; (8(4)):659-64 doi:10.1111/1751-7915.12275.

Validation of reference genes for real-time quantitative RT-PCR studies in Talaromyces marneffei.

Dankai W, Pongpom M, Vanittanakom N

Journal of microbiological methods 2015; (118()):42-50.

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.

Bicanic T, Bottomley C, Loyse A, et al.

Antimicrobial agents and chemotherapy 2015; (59(12)):7224-31 doi:10.1128/AAC.01698-15.

Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients.

Chan JF, Lau SK, Yuen KY, Woo PC

Emerging microbes & infections 2016; (5()):e19 doi:10.1038/emi.2016.18.

First-in-man observation of Talaromyces marneffei-transmission by organ transplantation.

Hermans F, Ombelet S, Degezelle K, et al.

Mycoses 2017; (60(3)):213-217 doi:10.1111/myc.12574.

Talaromyces marneffei Mp1p Is a Virulence Factor that Binds and Sequesters a Key Proinflammatory Lipid to Dampen Host Innate Immune Response.

Sze KH, Lam WH, Zhang H, et al.

Cell chemical biology 2017; (24(2)):182-194 doi:10.1016/j.chembiol.2016.12.014.

A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.

Le T, Kinh NV, Cuc NTK, et al.

The New England journal of medicine 2017; (376(24)):2329-2340 doi:10.1056/NEJMoa1613306.

Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.

Groll AH, Townsend R, Desai A, et al.

Transplant infectious disease : an official journal of the Transplantation Society 2017; (19(5)) doi:10.1111/tid.12751.

Macrophages protect Talaromyces marneffei conidia from myeloperoxidase-dependent neutrophil fungicidal activity during infection establishment in vivo.

Ellett F, Pazhakh V, Pase L, et al.

PLoS pathogens 2018; (14(6)):e1007063 doi:10.1371/journal.ppat.1007063.

MADS-Box Transcription Factor MadsA Regulates Dimorphic Transition, Conidiation, and Germination of Talaromyces marneffei.

Wang Q, Du M, Wang S, et al.

Frontiers in microbiology 2018; (9()):1781 doi:10.3389/fmicb.2018.01781.

Mechanistic Assessment of the Effect of Omeprazole on the In Vivo Pharmacokinetics of Itraconazole in Healthy Volunteers.

Abuhelwa AY, Mudge S, Upton RN, Foster DJR

European journal of drug metabolism and pharmacokinetics 2019; (44(2)):201-215 doi:10.1007/s13318-018-0519-1.

Genomic analysis provides insights into the transmission and pathogenicity of Talaromyces marneffei.

Li Y, Luo H, Fan J, et al.

Fungal genetics and biology : FG & B 2019; (130()):54-61 doi:10.1016/j.fgb.2019.05.002.

Absence of cutaneous involvement in disseminated Talaromyces marneffei infection in an AIDS patient: a case report and literature review.

Pongpech N, Rotjanapan P

Infection and drug resistance 2019; (12()):1493-1499 doi:10.2147/IDR.S207819.

Clinical experience with new formulation SUBA®-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies.

Nield B, Larsen SR, van Hal SJ

The Journal of antimicrobial chemotherapy 2019; (74(10)):3049-3055 doi:10.1093/jac/dkz303.

Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.

Cao C, Xi L, Chaturvedi V

Mycopathologia 2019; (184(6)):709-720 doi:10.1007/s11046-019-00410-2.

Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing.

Pruksaphon K, Intaramat A, Ratanabanangkoon K, et al.

Diagnostic microbiology and infectious disease 2020; (96(3)):114959 doi:10.1016/j.diagmicrobio.2019.114959.

Laboratory Maintenance and Growth of Talaromyces marneffei.

Andrianopoulos A

Current protocols in microbiology 2020; (56(1)):e97 doi:10.1002/cpmc.97.

Non-HIV talaromycosis: Radiological and clinical analysis.

Li X, Hu W, Wan Q, et al.

Medicine 2020; (99(10)):e19185 doi:10.1097/MD.0000000000019185.

Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis.

Thu NTM, Chan JFW, Ly VT, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(2)):e330-e336 doi:10.1093/cid/ciaa826.

Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis.

Qin Y, Huang X, Chen H, et al.

BMC infectious diseases 2020; (20(1)):551 doi:10.1186/s12879-020-05260-8.

Is stopping secondary prophylaxis safe in HIV-positive talaromycosis patients? Experience from Myanmar.

Tun N, Mclean A, Deed X, et al.

HIV medicine 2020; (21(10)):671-673 doi:10.1111/hiv.12921.

Talaromycosis in a renal transplant recipient returning from South China.

Vergidis P, Rao A, Moore CB, et al.

Transplant infectious disease : an official journal of the Transplantation Society 2021; (23(1)):e13447 doi:10.1111/tid.13447.

Talaromycosis clinically and histopathologically mimicking histoplasmosis in an immunocompromised patient.

Widaty S, Santoso ID, Ricky D, et al.

Dermatology online journal 2020; (26(9)).

Occult Talaromyces marneffei Infection Unveiled by the Novel Mp1p Antigen Detection Assay.

Ly VT, Thanh NT, Thu NTM, et al.

Open forum infectious diseases 2020; (7(11)):ofaa502 doi:10.1093/ofid/ofaa502.

Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment.

Kaewpoowat Q, Chaiwarith R, Yasri S, et al.

The Journal of antimicrobial chemotherapy 2021; (76(4)):1041-1045 doi:10.1093/jac/dkaa521.

Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.

Ying RS, Le T, Cai WP, et al.

HIV medicine 2020; (21(11)):729-738 doi:10.1111/hiv.13024.

Efficacy of different antifungal drugs as initial treatment for patients with talaromycosis: A systematic review and meta-analysis.

Sheng L, Shen Q, Zhou J

Journal de mycologie medicale 2021; (31(1)):101108 doi:10.1016/j.mycmed.2020.101108.

The novel Dbl homology/BAR domain protein, MsgA, of Talaromyces marneffei regulates yeast morphogenesis during growth inside host cells.

Weerasinghe H, Bugeja HE, Andrianopoulos A

Scientific reports 2021; (11(1)):2334 doi:10.1038/s41598-020-79593-4.

Pulmonary Talaromycosis: A Window into the Immunopathogenesis of an Endemic Mycosis.

Narayanasamy S, Dougherty J, van Doorn HR, Le T

Mycopathologia 2021; (186(5)):707-715 doi:10.1007/s11046-021-00570-0.

Talaromyces marneffei promotes M2-like polarization of human macrophages by downregulating SOCS3 expression and activating the TLR9 pathway.

Wei W, Ning C, Huang J, et al.

Virulence 2021; (12(1)):1997-2012 doi:10.1080/21505594.2021.1958470.

Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.

Stott KE, Le T, Nguyen T, et al.

Antimicrobial agents and chemotherapy 2021; (65(11)):e0063621 doi:10.1128/AAC.00636-21.

Metagenomic next-generation sequencing for the early diagnosis of talaromycosis in HIV-uninfected patients: five cases report.

Chen Q, Qiu Y, Zeng W, et al.

BMC infectious diseases 2021; (21(1)):865 doi:10.1186/s12879-021-06551-4.

Cutaneous manifestations and dermoscopic findings are important clues to the diagnosis of Talaromyces marneffei in HIV patients with immune reconstitution inflammatory syndrome: A case report and literature review.

Chaisuwannarak K, Chularojanamontri L, Junsuwan N, Eimpunth S

The Journal of dermatology 2022; (49(1)):168-172 doi:10.1111/1346-8138.16197.

A global call for talaromycosis to be recognised as a neglected tropical disease.

Narayanasamy S, Dat VQ, Thanh NT, et al.

The Lancet. Global health 2021; (9(11)):e1618-e1622 doi:10.1016/S2214-109X(21)00350-8.

Talaromyces Marneffei Infection in Lung Cancer Patients with Positive AIGAs: A Rare Case Report.

Lin F, Yang Z, Qiu Y, et al.

Infection and drug resistance 2021; (14()):5005-5013 doi:10.2147/IDR.S340694.

HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?

Qin Y, Zhou Y, Liu S, et al.

The Journal of infection 2022; (84(3)):410-417 doi:10.1016/j.jinf.2021.12.032.

Nodular Sclerosing Hodgkin Lymphoma Combined with Disseminated Talaromyces marneffei Infection: A Case Report.

Yang Z, Zeng W, Qiu Y, et al.

Infection and drug resistance 2021; (14()):5671-5678 doi:10.2147/IDR.S340192.

Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.

Xue X, Zou J, Fang W, et al.

Mycopathologia 2022; (187(2-3)):169-180 doi:10.1007/s11046-021-00614-5.

Disseminated talaromycosis complicated by recurrent gastrointestinal bleeding and hemorrhagic shock: a case report.

Cui X, Su F, Ye H, et al.

BMC infectious diseases 2022; (22(1)):238 doi:10.1186/s12879-022-07230-8.

Unusual disseminated Talaromyces marneffei infection presenting with fever and diarrhea in an AIDS patient: a case report and literature review.

Tan Y, Zhang Z, Wu M, et al.

Acta clinica Belgica 2023; (78(1)):67-70 doi:10.1080/17843286.2022.2067957.

Rapid diagnosis of Talaromyces marneffei infection by metagenomic next-generation sequencing technology in a Chinese cohort of inborn errors of immunity.

Liu L, Sun B, Ying W, et al.

Frontiers in cellular and infection microbiology 2022; (12()):987692 doi:10.3389/fcimb.2022.987692.

CT findings of Talaromyces marneffei infection among HIV patients with lymphadenopathy.

Zhu XL, Tang GX, Liu XY, et al.

Frontiers in medicine 2022; (9()):930678 doi:10.3389/fmed.2022.930678.

Clinical performance of metagenomic next-generation sequencing for the rapid diagnosis of talaromycosis in HIV-infected patients.

Mao Y, Shen H, Yang C, et al.

Frontiers in cellular and infection microbiology 2022; (12()):962441 doi:10.3389/fcimb.2022.962441.

Gastrointestinal Talaromyces marneffei infection in a man with AIDS: A case report.

Peng R, Peng Z, Mou M, et al.

Medicine 2023; (102(14)):e33424 doi:10.1097/MD.0000000000033424.

Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study.

Zhou Y, Lu T, Li Y, et al.

BMC infectious diseases 2023; (23(1)):707 doi:10.1186/s12879-023-08394-7.

Clinical usefulness of metagenomic next-generation sequencing for Talaromyces marneffei diagnosis in China: a retrospective study.

Zhang X, Yao X, Chen H, et al.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2024; (43(7)):1367-1374 doi:10.1007/s10096-024-04856-1.

Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.

Morris AJ, Kim HY, Nield B, et al.

Medical mycology 2024; (62(6)) doi:10.1093/mmy/myad133.

Metagenomic Next-Generation Sequencing as an Effective Diagnostic Tool for Talaromycosis in HIV-Negative Patients.

Jiang L, Liang TW, Al-Odaini N, et al.

Mycopathologia 2024; (189(4)):63 doi:10.1007/s11046-024-00866-x.

Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity.

Xing S, Zhang Z, Liu C, et al.

Journal of clinical immunology 2024; (45(1)):17.

Clinical characteristics and prognosis of Talaromycosis marneffei associated immune reconstitution inflammatory syndrome in AIDS patients.

Zhang Q, Zhang H, Guo P, et al.

PLoS neglected tropical diseases 2024; (18(10)):e0012609 doi:10.1371/journal.pntd.0012609.

Amphotericin B Colloidal Dispersion is Efficacious and Safe for the Management of Talaromycosis in HIV-Infected Patients: Results of a Retrospective Cohort Study in China.

Liu M, Yang H, Liu Q, et al.

Infection and drug resistance 2024; (17()):5581-5593 doi:10.2147/IDR.S481856.

CD86 immunohistochemical staining for the detection of Talaromyces marneffei in lesions.

Fang J, Chen H, Hamal K, Liu D

Microbiology spectrum 2025; (13(4)):e0206324 doi:10.1128/spectrum.02063-24.

Talaromyces Marneffei infections in five human immunodeficiency virus-negative patients with the history of predation on wild bamboo rats (Rhizomys spp) - a case series.

Cao L, Sun Y, Zhou Z, Pan X

BMC infectious diseases 2025; (25(1)):340 doi:10.1186/s12879-025-10713-z.

Early differential diagnosis models of Talaromycosis and Tuberculosis in HIV-negative hosts using clinical data and machine learning.

Qiu Y, Li ZT, Yang SX, et al.

Journal of infection and public health 2025; (18(6)):102740 doi:10.1016/j.jiph.2025.102740.

Disseminated talaromycosis in HIV-negative patients with lung cancer: a rare case report and literature review.

He H, Cai L, Xue X, et al.

BMC infectious diseases 2025; (25(1)):601 doi:10.1186/s12879-025-10985-5.

The Impact of Dietary Interventions on the Pharmacokinetics of Antifungal Drugs: A Systematic Review with Meta-analyses.

Wiesner-Kiełczewska A, Zagrodzki P, Paśko P

Clinical pharmacokinetics 2025; (64(6)):815-848 doi:10.1007/s40262-025-01511-6.

An overview of rapid non-culture-based techniques in various clinical specimens for the laboratory diagnosis of Talaromyces marneffei.

Wei H, Thammasit P, Amsri A, et al.

Frontiers in cellular and infection microbiology 2025; (15()):1591429 doi:10.3389/fcimb.2025.1591429.

Comparative performance of a commercial and in-house Mp1p antigen-detecting enzyme immunoassay for the rapid diagnosis of talaromycosis.

Barwatt J, Brown L, Thu NTM, et al.

PLoS neglected tropical diseases 2025; (19(8)):e0013248 doi:10.1371/journal.pntd.0013248.

Loop-mediated isothermal amplification coupled with a nanoparticle-based lateral biosensor for rapid, sensitive, and specific detection of Talaromyces marneffei.

Zhou Y, Ye R, Wang Y, et al.

Frontiers in microbiology 2025; (16()):1661312 doi:10.3389/fmicb.2025.1661312.

Single high-dose liposomal amphotericin B plus B/F/TAF for AIDS-associated talaromycosis in China: a multicentre randomised controlled trial protocol.

Yan X, Meng X, Song W, et al.

BMJ open 2025; (15(11)):e105648 doi:10.1136/bmjopen-2025-105648.

Emergence of Next-Generation Sequencing for Laboratory Diagnosis of Talaromyces marneffei.

Xing F, Deng C, Luo Z, et al.

Mycopathologia 2025; (191(1)):12 doi:10.1007/s11046-025-01028-3.

Development and Clinical Evaluation of a Novel Talaromyces marneffei Mp1p Lateral Flow Assay for Rapid Diagnosis of Talaromycosis.

Thu NTM, Brown L, Hawkins O, et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026; doi:10.1093/cid/ciag004.

Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation.

Chastain DB, Anderson DT, Eudy J, et al.

The Journal of antimicrobial chemotherapy 2026; (81(3)) doi:10.1093/jac/dkag055.

Clinical characteristics and long-term prognosis of talaromycosis in children with novel and reported inborn errors of immunity.

Lu Q, Li X, Jiang Z, et al.

Frontiers in immunology 2026; (17()):1834635 doi:10.3389/fimmu.2026.1834635.

Successful Rescue Therapy for Talaromycosis Complicated by Severe Acute Hepatorenal Failure with Hepatic Encephalopathy in an HIV/HCV-Coinfected Patient: A Case Report.

Zou J, Qin XY, Zhang MY, et al.

Infection and drug resistance 2026; (19()):605910 doi:10.2147/IDR.S605910.

Multiple recurrences of Talaromyces marneffei infection with HLH in an HIV-negative patient: a case report.

Zhu L, Liu Y, Tao R, You L

BMC infectious diseases 2026; (26(1)).

Sequential Talaromyces marneffei and Legionella pneumophila infections leading to the diagnosis of anti-interferon-γ autoantibody-associated immunodeficiency: a case report.

Yu M, Xiao Y, Liu Y, et al.

BMC pulmonary medicine 2026; doi:10.1186/s12890-026-04455-0.

Talaromycosis-associated immune reconstitution inflammatory syndrome exhibits immune dysregulation in patients with acquired immunodeficiency syndrome.

Zhao B, Zhang Q, Guo P, et al.

PLoS neglected tropical diseases 2026; (20(9)):e0014695 doi:10.1371/journal.pntd.0014695.